Structural membrane protein synthesis technologies, revolutionary cell-free protein synthesis methods, have been developed by Prof. Shigeyuki Yokoyama, Emeritus Professor at The University of Tokyo and Distinguished Senior Scientist at RIKEN, scientific founder of LiberoThera.
The target membrane protein can be synthesized in vitro, with appropriate folding in natural form with structural and functional integrity, resulting in generation of small membrane fragment integrated with the target protein.
